艾昆纬-印度制药业务季度洞察——2025年第二季度（英）_12页_469kb

The IQVIA report for the Indian Pharmaceutical Business Quarterly Insights Q2 2025 highlights key performance indicators and market trends in the Indian pharmaceutical sector, published on August 2025. The report provides a detailed analysis of revenue growth and market dynamics as of June 2025.

Key Findings:

• Quarterly Revenue Growth: Many companies experienced growth or declines, with specific figures for firms like Dr. Reddy’s, Cipla, and Sun Pharma showing values around 53-57 INR Cr. The analysis compares Q2 2025 (Apr-Jun) to Q2 2024, noting varying performance trends.
• Market Dynamics: The pharmaceutical market saw mixed results, influenced by factors such as regulatory changes, domestic demand, healthcare infrastructure, and competition.
• Sector Analysis: Focus on generic drugs, formulations, and therapeutics was prominent. Key factors included pricing pressures, supply chain resilience, government policies like PM Modi’s initiatives, and COVID-19 legacy.
• Market Segments: Reports emphasize the balance between domestic generic sales and exports, with increasing focus on specialty and innovative medicines.

Notable Company Performance:

• Major players like Dr. Reddy’s, Cipla, Zydus Cadila, and Lupin demonstrated resilience but faced challenges such as revenue volatility and pricing pressures.
• Smaller firms showed niche strengths, while healthcare infrastructure support and vaccination programs post-COVID contributed to overall sector growth.

Recommendations:

• Companies are advised to invest in innovation and R&D, optimize supply chains, and adhere to regulatory oversight to sustain growth amid economic challenges.

This report underscores both opportunities and risks in the Indian pharmaceutical industry, reflecting its volatility and potential for recovery post-pandemic. Data is based on TSA June 2025 dataset, with applicable disclaimers.